Xenon Pharmaceuticals Inc. (XENE), a neuroscience-focused biopharmaceutical company, is approaching a key milestone, representing a critical step toward regulatory submission, potential approval, and the company's first commercial launch.
The company's lead drug candidate is Azetukalner, which is being explored in the indications of epilepsy, major depressive disorder, and bipolar depression.
Azetukalner works by targeting specific channels in the brain that are involved in regulating electrical activity. By modulating these channels, it may help to reduce the occurrence of seizures in people with epilepsy. (Source: ClinicalTrials.eu).
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.